Uridine di- or tri-phosphate derivatives and uses thereof
US-9221868-B2 · Dec 29, 2015 · US
US10597422B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10597422-B2 |
| Application number | US-201916248273-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 15, 2019 |
| Priority date | Feb 8, 2016 |
| Publication date | Mar 24, 2020 |
| Grant date | Mar 24, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention is directed to a process for making Chloro-Substituted Nucleoside Phosphoramidate Compounds of formula (I): which are useful for the treatment and prophylaxis of HCV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).
Opening claim text (preview).
What is claimed is: 1. A compound having the formula: X is selected from C 1 -C 6 alkylene, C 6 -C 10 arylene, C 4 -C 10 cycloalkylene, 5 or 6-membered monocyclic heteroarylene and 9 or 10-membered bicyclic heteroarylene, wherein said C 6 -C 10 arylene group, said C 4 -C 10 cycloalkylene group, said 5 or 6-membered monocyclic heteroarylene group and said 9 or 10-membered bicyclic heteroarylene group can be optionally substituted with one or more R 5 groups; each occurrence of R 5 is independently selected from —C 1 -C 6 alkyl, halo, —OR 6 , —C(O)R 6 , —CO 2 R 6 , —SR 6 , —C 1 -C 6 hydroxyalkyl, —C 1 -C 6 haloalkyl, —N(R 6 ) 2 , —S(O)R 6 , —S(O) 2 R 6 , —CN and —NO 2 ; each occurrence of R 6 is independently selected from H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, —(C 1 -C 3 alkylene) m -(C 3 -C 7 cycloalkyl), —(C 1 -C 3 alkylene) m -(C 6 -C 10 aryl), —(C 1 -C 3 alkylene) m -(4 to 7-membered heterocycloalkyl), —(C 1 -C 3 alkylene) m -(5- or 6-membered monocyclic heteroaryl) and —(C 1 -C 3 alkylene) m -(9- or 10-membered bicyclic heteroaryl); each occurrence of R 7 is independently selected from H, C 1 -C 6 alkyl, phenyl, C 3 -C 7 cycloalkyl, 4 to 7-membered monocyclic heterocycloalkyl and 5- or 6-membered monocyclic heteroaryl; each occurrence of R 8 is independently selected from H, C 1 -C 6 alkyl, phenyl, C 3 -C 7 cycloalkyl, 4 to 7-membered monocyclic heterocycloalkyl and 5- or 6-membered monocyclic heteroaryl; each occurrence of m is independently 0 or 1; p is 2, 3, 4 or 5; and q is 2, 3, 4 or 5. 2. The compound of claim 1 , having the structure:
with the saccharide radical esterified by phosphoric or polyphosphoric acids · CPC title
Phosphorylation · CPC title
Ortho-condensed systems · CPC title
Processes for the preparation of sugar derivatives · CPC title
the hetero ring containing nitrogen as ring hetero atoms · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.